HIV-1 tat protein induces PD-l1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms

Journal of Virology

Volumn 88, Issue 12, 2014, Pages 6672-6689

  Planès, Rémi ^a,b,c   BenMohamed, Lbachir ^d   Leghmari, Kaoutar ^a,b,c   Delobel, Pierre ^a,b,c,e   Izopet, Jacques ^a,b,c,f   Bahraoui, Elmostafa ^a,b,c  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 4; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVITY; CELL CONTACT; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR SIGNALING; KNOCKOUT MOUSE; MONOCYTE DERIVED DENDRITIC CELL; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; WILD TYPE;

AMINO ACID MOTIFS; ANIMALS; ANTIGENS, CD274; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84901362621     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00825-14     Document Type: Article

References (80)

1. Luban J. 2012. Innate immune sensing of HIV-1 by dendritic cells. Cell Host Microbe 12:408-418. http://dx.doi.org/10.1016/j.chom.2012.10.002.
2. Swanstrom R, Coffin J. 2012. HIV-1 pathogenesis: the virus. Cold Spring Harb. Perspect. Med. 2:a007443. http://dx.doi.org/10.1101/cshperspect.a007443.
3. Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H.2010. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat. Rev. Microbiol. 8:350-360. http://dx.doi.org/10.1038/nrmicro2332.
4. Liu B, Woltman AM, Janssen HL, Boonstra A. 2009. Modulation of dendritic cell function by persistent viruses. J. Leukoc. Biol. 85:205-214. http://dx.doi.org/10.1189/jlb.0408241.
5. Reise Sousa C. 2006. Dendritic cells in a mature age. Nat. Rev. Immunol. 6:476-483. http://dx.doi.org/10.1038/nri1845.
6. Miller E, Bhardwaj N. 2013. Dendritic cell dysregulation during HIV-1 infection. Immunol. Rev. 254:170-189. http://dx.doi.org/10.1111/imr.12082.
7. Wijewardana V, KristoffJ, Xu C, Ma D, Haret-Richter G, Stock JL, Policicchio BB, Mobley AD, Nusbaum R, Aamer H, Trichel A, RibeiroRM, Apetrei C, Pandrea I. 2013. Kinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections. PLoS Pathog. 9:e1003600. http://dx.doi.org/10.1371/journal.ppat.1003600.
8. Appay V, Sauce D. 2008. Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol. 214:231-241. http://dx.doi.org/10.1002/path.2276.
9. Ipp H, Zemlin A. 2013. The paradox of the immune response in HIV infection: when inflammation becomes harmful. Clin. Chim. Acta 416: 96-99. http://dx.doi.org/10.1016/j.cca.2012.11.025.
10. Khaitan A, Unutmaz D. 2011. Revisiting immune exhaustion during HIV infection. Curr. HIV/AIDS Rep. 8:4-11. http://dx.doi.org/10.1007/s11904-010-0066-0.
11. Sauce D, Elbim C, Appay V. 2013. Monitoring cellular immune markers in HIV infection: from activation to exhaustion. Curr. Opin. HIV AIDS 8:125-131. http://dx.doi.org/10.1097/COH.0b013e32835d08a9.
12. Herbeuval JP, Shearer GM. 2007. HIV-1 immunopathogenesis: how good interferon turns bad. Clin. Immunol. 123:121-128. http://dx.doi.org/10.1016/j.clim.2006.09.016.
13. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. 2011. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J. Exp. Med. 208:2367-2374. http://dx.doi.org/10.1084/jem.20110654.
14. Wijewardana V, SoloffAC, Liu X, Brown KN, Barratt-Boyes SM. 2010. Early myeloid dendritic cell dysregulation is predictive of disease progression in simian immunodeficiency virus infection. PLoS Pathog. 6:e1001235. http://dx.doi.org/10.1371/journal.ppat.1001235.
15. Katsikis PD, Mueller YM, Villinger F. 2011. The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog. 7:e1002055. http://dx.doi.org/10.1371/journal.ppat.1002055.
16. Keating SM, Jacobs ES, Norris PJ. 2012. Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth Factor Rev. 23:193-206. http://dx.doi.org/10.1016/j.cytogfr.2012.05.006.
17. Freeman GJ. 2008. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc. Natl. Acad. Sci. U. S. A. 105:10275-10276. http://dx.doi.org/10.1073/pnas.0805459105.
18. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203:2223-2227. http://dx.doi.org/10.1084/jem.20061800.
19. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687. http://dx.doi.org/10.1038/nature04444.
20. Xu H, Wang X, Pahar B, Moroney-Rasmussen T, Alvarez X, Lackner AA, Veazey RS. 2010. Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. J. Immunol. 185:7340-7348. http://dx.doi.org/10.4049/jimmunol.1001642.
21. Estes JD, Gordon SN, Zeng M, Chahroudi AM, Dunham RM, Staprans SI, Reilly CS, Silvestri G, Haase AT. 2008. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J. Immunol. 180:6798-6807.
22. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704. http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331.
23. Wang X, Zhang Z, Zhang S, Fu J, Yao J, Jiao Y, Wu H, Wang FS. 2008. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur. J. Immunol. 38:3226-3236. http://dx.doi.org/10.1002/eji.200838285.
24. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81:4215-4225. http://dx.doi.org/10.1128/JVI.02844-06.
25. Shen T, Chen X, Chen Y, Xu Q, Lu F, Liu S. 2010. Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection. J. Med. Virol. 82: 1152-1159. http://dx.doi.org/10.1002/jmv.21809.
26. ChentoufiAA, Dervillez X, Dasgupta G, Nguyen C, Kabbara KW, Jiang X, Nesburn AB, Wechsler SL, BenMohamed L. 2012. The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells. Viral Immunol. 25:204-215. http://dx.doi.org/10.1089/vim.2011.0091.
27. ChentoufiAA, Kritzer E, Tran MV, Dasgupta G, Lim CH, Yu DC, AfifiRE, Jiang X, Carpenter D, Osorio N, Hsiang C, Nesburn AB, Wechsler SL, BenMohamed L. 2011. The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8α T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. J. Virol. 85:9127-9138. http://dx.doi.org/10.1128/JVI.00587-11.
28. Channappanavar R, Twardy BS, Suvas S. 2012. Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection. PLoS One 7:e39757. http://dx.doi.org/10.1371/journal.pone.0039757.
29. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354. http://dx.doi.org/10.1038/nature05115.
30. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, Amara RR. 2012. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Invest. 122:1712-1716. http://dx.doi.org/10.1172/JCI60612.
31. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP. 2006. Upregulation of PD-1 expression on HIV-specific CD8α T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202. http://dx.doi.org/10.1038/nm1482.
32. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ, Ahmed R, Amara RR. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206-210. http://dx.doi.org/10.1038/nature07662.
33. Badou A, Bennasser Y, Moreau M, Leclerc C, Benkirane M, Bahraoui E. 2000. Tat protein of human immunodeficiency virus type 1 induces interleukin- 10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J. Virol. 74:10551-10562. http://dx.doi.org/10.1128/JVI.74.22.10551-10562.2000.
34. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B. 1992. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 66:7159-7167.
35. Buscemi L, Ramonet D, Geiger JD. 2007. Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity. Neurobiol. Dis. 26:661-670. http://dx.doi.org/10.1016/j.nbd.2007.03.004.
36. Contreras X, Bennasser Y, Bahraoui E. 2004. IL-10 production induced by HIV-1 Tat stimulation of human monocytes is dependent on the activation of PKC beta(II) and delta isozymes. Microbes Infect. 6:1182-1190. http://dx.doi.org/10.1016/j.micinf.2004.06.008.
37. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, Ensoli B. 2002. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigenspecific T cell responses. J. Immunol. 168:197-206.
38. Gandhi N, Saiyed Z, Thangavel S, Rodriguez J, Rao KV, Nair MP. 2009. Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res. Hum. Retroviruses 25:691-699. http://dx.doi.org/10.1089/aid.2008.0299.
39. Gee K, Angel JB, Ma W, Mishra S, Gajanayaka N, Parato K, Kumar A. 2006. Intracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells. J. Biol. Chem. 281:31647-31658. http://dx.doi.org/10.1074/jbc. M512109200.
40. Gupta S, Boppana R, Mishra GC, Saha B, Mitra D. 2008. HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner. J. Immunol. 180:79-88.
41. Johri MK, Mishra R, Chhatbar C, Unni SK, Singh SK. 2011. Tits and bits of HIV Tat protein. Expert Opin. Biol. Ther. 11:269-283. http://dx.doi.org/10.1517/14712598.2011.546339.
42. Leghmari K, Bennasser Y, Tkaczuk J, Bahraoui E. 2008. HIV-1 Tat protein induces IL-10 production by an alternative TNF-alpha-independent pathway in monocytes: role of PKC-delta and p38 MAP kinase. Cell Immunol. 253:45-53. http://dx.doi.org/10.1016/j.cellimm.2008.04.015.
43. Rubartelli A, Poggi A, Sitia R, Zocchi MR. 1998. HIV-I Tat: a polypeptide for all seasons. Immunol. Today 19:543-545. http://dx.doi.org/10.1016/S0167-5699(98)01351-6.
44. Goldstein G. 1996. HIV-1 Tat protein as a potential AIDS vaccine. Nat. Med. 2:960-964. http://dx.doi.org/10.1038/nm0996-960.
45. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, Krammer PH. 1995. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497-500. http://dx.doi.org/10.1038/375497a0.
46. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT. 2000. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 97:11466-11471. http://dx.doi.org/10.1073/pnas.97.21.11466.
47. Tyagi M, Rusnati M, Presta M, Giacca M. 2001. Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:3254-3261. http://dx.doi.org/10.1074/jbc. M006701200.
48. Noonan D, Albini A. 2000. From the outside in: extracellular activities of HIV Tat. Adv. Pharmacol. 48:229-250. http://dx.doi.org/10.1016/S1054-3589(00)48008-7.
49. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:277-287.
50. Campbell GR, Loret EP, Spector SA. 2010. HIV-1 clade B Tat, but not cladeCTat, increases X4 HIV-1 entry into resting but not activated CD4α T cells. J. Biol. Chem. 285:1681-1691. http://dx.doi.org/10.1074/jbc. M109.049957.
51. Zheng L, Yang YD, Lu GC, Salvato MS. 2005. Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes. J. Zhejiang Univ. Sci. B 6:668-672. http://dx.doi.org/10.1631/jzus.2005.B0668.
52. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, Pardee AB. 1997. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 94:8116-8120. http://dx.doi.org/10.1073/pnas.94.15.8116.
53. King JE, Eugenin EA, Buckner CM, Berman JW. 2006. HIV Tat and neurotoxicity. Microbes Infect. 8:1347-1357. http://dx.doi.org/10.1016/j.micinf.2005.11.014.
54. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, Geiger JD. 1996. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 70:1475-1480.
55. Sabatier JM, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, Hue B, Bahraoui E. 1991. Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1. J. Virol. 65:961-967.
56. Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V, Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, Yirrell DL, Loret EP. 2004. The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J. Biol. Chem. 279:48197-48204. http://dx.doi.org/10.1074/jbc. M406195200.
57. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB. 1995. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268: 429-431. http://dx.doi.org/10.1126/science.7716549.
58. Gutheil WG, Subramanyam M, Flentke GR, Sanford DG, Munoz E, Huber BT, Bachovchin WW. 1994. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc. Natl. Acad. Sci. U. S. A. 91: 6594-6598. http://dx.doi.org/10.1073/pnas.91.14.6594.
59. Contreras X, Bennasser Y, Chazal N, Moreau M, Leclerc C, Tkaczuk J, Bahraoui E. 2005. Human immunodeficiency virus type 1 Tat protein induces an intracellular calcium increase in human monocytes that requires DHP receptors: involvement in TNF-alpha production. Virology 332:316-328. http://dx.doi.org/10.1016/j.virol.2004.11.032.
60. Zocchi MR, Poggi A, Rubartelli A. 1997. The RGD-containing domain of exogenous HIV-1 Tat inhibits the engulfment of apoptotic bodies by dendritic cells. AIDS 11:1227-1235. http://dx.doi.org/10.1097/00002030-199710000-00005.
61. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, Bussolino F. 1996. The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat. Med. 2:1371-1375. http://dx.doi.org/10.1038/nm1296-1371.
62. Haij NB, Leghmari K, Planes R, Thieblemont N, Bahraoui E. 2013. HIV-1 Tat protein binds to TLR4-MD2 and signals to induce TNF-alpha and IL-10. Retrovirology 10:123. http://dx.doi.org/10.1186/1742-4690-10-123.
63. Vives E, Charneau P, van Rietschoten J, Rochat H, Bahraoui E. 1994. Effects of the Tat basic domain on human immunodeficiency virus type 1 transactivation, using chemically synthesized Tat protein and Tat peptides. J. Virol. 68:3343-3353.
64. Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, Sela J, Porichis F, Le Gall S, Waring MT, Moss K, Jessen H, Pereyra F, Kavanagh DG, Walker BD, Kaufmann DE. 2009. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 114:346-356. http://dx.doi.org/10.1182/blood-2008-12-191296.
65. Wang XC, Fan YS, Zhou ZQ, Li HQ, Zhang Z, Zhang T, Wang L, Yang XP, Mao L, Xie RH, Lei SY, Wu H, Wang FS. 2010. Expression of B7-H1 on peripheral myeloid dendritic cells in patients with HIV infection and its correlation with diseases progression. Zhonghua Yi Xue Za Zhi 90:588-592. (In Chinese.)
66. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. 2010. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2:32ra36. http://dx.doi.org/10.1126/scitranslmed.3000632.
67. Bennasser Y, Badou A, Tkaczuk J, Bahraoui E. 2002. Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha. Virology 303:174-180. http://dx.doi.org/10.1006/viro.2002.1676.
68. Leghmari K, Bennasser Y, Bahraoui E. 2008. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. Eur. J. Cell Biol. 87:947-962. http://dx.doi.org/10.1016/j.ejcb.2008.06.005.
69. Samikkannu T, Rao KV, Gandhi N, Saxena SK, Nair MP. 2010. Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: implications for neuroAIDS. J. Neurovirol. 16:255-263. http://dx.doi.org/10.3109/13550284.2010.497809.
70. Samikkannu T, Saiyed ZM, Rao KV, Babu DK, Rodriguez JW, Papuashvili MN, Nair MP. 2009. Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res. Hum. Retroviruses 25:329-335. http://dx.doi.org/10.1089/aid.2008.0225.
71. Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B. 2009. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J. Immunol. 182:2888-2897. http://dx.doi.org/10.4049/jimmunol.0711406.
72. Jain P, Ahuja J, Khan ZK, Shimizu S, Meucci O, Jennings SR, Wigdahl B. 2007. Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. J. Leukoc. Biol. 82:44-56. http://dx.doi.org/10.1189/jlb.1006641.
73. Majumder B, Janket ML, Schafer EA, Schaubert K, Huang XL, Kan-Mitchell J, Rinaldo CR, Jr, Ayyavoo V. 2005. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J. Virol. 79:7990-8003. http://dx.doi.org/10.1128/JVI.79.13.7990-8003.2005.
74. Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA, Aldovini A. 2003. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat. Med. 9:191-197. http://dx.doi.org/10.1038/nm822.
75. Xu H, Wang X, Pahar B, Moroney-Rasmussen T, Alvarez X, Lackner AA, Veazey RS. 2010. Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. J. Immunol. 185:7340-7348. http://dx.doi.org/10.4049/jimmunol.1001642.
76. Larsson M, Shankar EM, Che KF, Saeidi A, Ellegard R, Barathan M, Velu V, Kamarulzaman A. 2013. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology 10:31. http://dx.doi.org/10.1186/1742-4690-10-31.
77. Shankar EM, Che KF, Messmer D, Lifson JD, Larsson M. 2011. Expression of a broad array of negative costimulatory molecules and Blimp-1 in T-cells following priming by HIV-1 pulsed dendritic cells. Mol. Med. 17: 229-240. http://dx.doi.org/10.2119/molmed.2010.00175.
78. Planes R, Bahraoui E. 2013. HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation. PLoS One 8:e74551. http://dx.doi.org/10.1371/journal.pone.0074551.
79. Palmer BE, NeffCP, Lecureux J, Ehler A, Dsouza M, Remling-Mulder L, Korman AJ, Fontenot AP, Akkina R. 2013. In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4α T cell levels in humanized mice. J. Immunol. 190:211-219. http://dx.doi.org/10.4049/jimmunol.1201108.
80. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134-144. http://dx.doi.org/10.1056/NEJMoa1305133.